The combination of pembrolizumab and enfortumab vedotin shows promise as a first-line therapy for advanced urothelial carcinoma. Enfortumab vedotin targets nectin-4, in turn enhancing T cell and natural killer cell activity, inhibiting immunosuppressive pathways and impeding tumour evasion. This synergy with pembrolizumab shows potential in enhancing immunotherapy for these patients.

中文翻译：

---

帕博利珠单抗联合 enfortumab vedotin 治疗尿路上皮癌

pembrolizumab 和 enfortumab vedotin 的组合有望成为晚期尿路上皮癌的一线疗法。Enfortumab vedotin 以 nectin-4 为靶点，进而增强 T 细胞和自然杀伤细胞的活性，抑制免疫抑制途径并阻止肿瘤逃避。与派姆单抗的协同作用显示出增强这些患者免疫治疗的潜力。